lung disease

Sponsored Post

Physician Targeting Using Real-time Data: How PurpleLab’s Alerts Can Help

By leveraging real-time data that offers unprecedented insights into physician behavior and patient outcomes, companies can gain a competitive advantage with prescribers. PurpleLab®, a healthcare analytics platform with one of the largest medical and pharmaceutical claims databases in the United States, recently announced the launch of Alerts which translates complex information into actionable insights, empowering companies to identify the right physicians to target, determine the most effective marketing strategies and ultimately improve patient care.


BMY partners with Duke University on clinical trial for lung disease drug

A Bristol-Myers Squibb (NYSE:BMY) lung disease drug candidate is moving ahead in clinical development under a new partnership with Duke University. Under the alliance, Bristol-Myers scientists will work with the Duke Translational Medicine Institute on phase 2 clinical development of BMS-986202, a compound being studied as a treatment for idiopathic pulmonary fibrosis or IPF. A […]